Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist

Surging demand for Eli Lilly's (LLY.N) diabetes drug Mounjaro, which is also being used off-label for weight loss, led to a surprise third-quarter profit, but the drugmaker on Thursday said it expects supply constraints for some time as it adds manufacturing capacity.